Home › Compound Library › Pravastatin

Pravastatin

Statinprescriptionoral · inferred

Hydrophilic HMG-CoA reductase inhibitor, minimally CYP-metabolized and featured prominently in longevity and cardiovascular literature. Less lipophilic than atorvastatin/simvastatin, reducing CNS and muscle penetration and potentially myopathy risk. Typical 10-80 mg once daily at bedtime. WOSCOPS and LIPID established primary and secondary prevention benefits.

Projected serum levels — 40 mg, once daily

Pravastatin
Pravastatin modeled serum levels, 40 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 40 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 4.8 mg, trough ≈ 0.001 mg body load. Population-based estimate over 15 days for a 40 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Statin
Route modeled
Oral
Model confidence
inferred
Half-life
1.8 h
Common dose
40 mg
Suggested maximum
80 mg/day
Reference dose range
10–80 mg (single dose)
Suggested cadence
once daily
Validated against
40 mg oral — Cmax 0.045 mg/L at 1 h

Documented interactions

  • moderate
    Apigenin + Pravastatin Transporter inhibition

    Apigenin inhibitor of BCRP may alter Pravastatin absorption / distribution

  • moderate
    Entacapone (Comtan) + Pravastatin Transporter inhibition

    Entacapone (Comtan) inhibitor of OATP1B1 may alter Pravastatin absorption / distribution

  • moderate
    Fisetin + Pravastatin Transporter inhibition

    Fisetin inhibitor of BCRP may alter Pravastatin absorption / distribution

  • moderate
    Glecaprevir + Pravastatin Transporter inhibition

    Glecaprevir inhibitor of OATP1B1 may alter Pravastatin absorption / distribution

  • moderate
    Green Tea Extract (Camellia sinensis) + Pravastatin Transporter inhibition

    Green Tea Extract (Camellia sinensis) inhibitor of OATP1B1 may alter Pravastatin absorption / distribution

  • moderate
    Pibrentasvir + Pravastatin Transporter inhibition

    Pibrentasvir inhibitor of BCRP may alter Pravastatin absorption / distribution

Serum checks 17 modeled interaction pairings for pravastatin across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia Shepherd J et al. (WOSCOPS Study Group) · New England Journal of Medicine, 1995 DOI

    WOSCOPS primary-prevention RCT of 6595 hypercholesterolemic men showed pravastatin 40 mg reduced nonfatal MI or CHD death by 31% over 4.9 years.

  2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels (LIPID) LIPID Study Group · New England Journal of Medicine, 1998 DOI

    LIPID secondary-prevention RCT of 9014 patients with prior MI or unstable angina showed pravastatin 40 mg reduced CHD mortality by 24% and overall mortality by 22% over 6.1 years.

  3. Clinical pharmacokinetics and pharmacodynamics of pravastatin Hatanaka T · Clinical Pharmacokinetics, 2000 DOI

    PK review establishing pravastatin's ~17% oral bioavailability, 1.5-2 hour half-life, hepatic selectivity via OATP1B1 uptake, and minimal CYP3A4 interaction liability.

  4. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Cholesterol Treatment Trialists Collaboration · Lancet, 2010 DOI

    Meta-analysis of 26 statin trials (170,000 patients) found each 1 mmol/L LDL reduction reduced major vascular events by 22%, major coronary events by 24%, and stroke by 15%, with benefit consistent across pravastatin,…

4 published studies referenced in the app, each with a plain-language summary.